Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hormel Foods Corp (HRL) vs Novo Nordisk A/S (NVO) Price & Performance

Hormel Foods CorpTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Hormel Foods Corp vs Novo Nordisk A/S — how do they compare? Hormel Foods Corp trades at $24.37 (market cap $13.37B), while Novo Nordisk A/S trades at $46.21 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 15.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.

HRLNVO
Market Cap
$13.37B$207.85B
Sector
Consumer StaplesHealth
52-Week High
$29.25$63.98
52-Week Low
$19.74$35.29
Enterprise Value
$15.37B$222.55B
Dividend Yield
4.81%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hormel Foods Corp

Hormel Foods (HRL) trades at $24.23, down 1.92% over 24 hours, amid a bearish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $0.40 surpassing the $0.3544 estimate. Revenue for 2025 was $12.11B, though net income margin compressed to 3.82%. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its CERATTI business in Brazil.

HRL presents a mixed outlook with a defensive profile as a consumer staple, supported by a 4.6% dividend yield. However, margin pressures and a bearish technical trend pose near-term risks. The consensus price target of $26.33 implies modest upside, but investor sentiment remains cautious given high hold ratings.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hormel Foods Corp

Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.

Read more on HRL

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO